You must log in or register to see images
Can ignore the 90% effectiveness rating for AZ, based on a dose that no one will be getting.
There’s no two ways about it it’s not as good as the Pfizer and Moderna vaccines, or even the Russian one if we are to believe the data on that, but it is cheap and allegedly available and considerably better than nothing. From what I understand it’s about as effective as standard vaccines for other diseases, which require very high uptake to have an impact on disease spreading. The professor is right, it is a massive step forward, particularly given the time that it took to develop, and I will queue up to get it when it is offered. I’d prefer to get the Pfizer one, and I’m very glad that my mum is having that one, but the key thing is that as many people as possible have some level of protection as quickly as possible.
I have probably missed it, but I haven’t seen any figures on how effective a single jab is. If two doses give 62% protection a single dose has to be lower than that, which is probably why they are talking about reducing the risk of serious disease/hospitalisation rather than absolute protection. Which should at least help ‘protect the NHS’. If this jab makes the virus akin in seriousness to the common cold in those who develop symptoms, I’ll take that.
My concerns are more boring and about the regulatory process, but that’s because it’s a little bit of my job. The safety and overall effectiveness are exactly as expected. The dosing regime, specifically the gap between doses (which I see is approved at ‘between 4 and 12 weeks’) isn’t.
How will you feel if the FDA in the US does not approve the AZ jab? It’s based on old technology and the FDA has never approved a vaccine using the same approach before. Mind you it had never approved anything using the Pfizer approach either, but that is a brand new technology.